



NDA 019152/S-044

## SUPPLEMENT APPROVAL

Pfizer, Inc.  
Attention: Nataly Zarate  
US Regulatory Strategist Manager  
235 East 42<sup>nd</sup> Street  
New York, NY 10017

Dear Ms. Zarate:

Please refer to your supplemental new drug application (sNDA) dated and received September 11, 2019, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Calan SR (verapamil hydrochloride) 120 mg, 180 mg and 240 mg tablets.

This Prior Approval supplemental new drug application provides revisions to the WARNINGS, Drug Interaction section of the approved labeling to add information regarding clinically significant effects of Cytochrome inducers/inhibitors.

### **APPROVAL & LABELING**

We have completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Lori Anne Wachter, RN, BSN, RAC  
Regulatory Project Manager for Safety  
301 796-3975

Sincerely,

*{See appended electronic signature page}*

Mary Ross Southworth, PharmD.  
Deputy Director for Safety  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

MARY R SOUTHWORTH  
10/28/2019 12:22:33 PM